CompoAtlas

Extrait hydro-alcoolique de grande camomille 50 ml

Food supplement declared in France, decision dated 23 December 2025

Extrait hydro-alcoolique de grande camomille 50 ml (Les enracinées) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Tanacetum parthenium 1.3 g per day. None of the rules we check flags an issue with its declared composition.

Brand
Les enracinées
Food business operator placing the product on the market
Laetitia Modine
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Dropper
Daily dose
60 gouttes (soit 3 ml)
Directions for use
Solution buvable en gouttes. Dose journalière recommandée : 10 gouttes, 2 à 3 fois par jour, à diluer dans un peu d'eau, en dehors des repas, durant de 21 jours, renouvelable après une semaine d’arrêt. Dose journalière maximale : 60 gouttes (3 ml), soit environ 1,3 g de grande camomille fraîche.
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Taking away from meals, Pregnant women, Taking anticoagulants
Objectives stated by the manufacturer (these are not authorised claims)
Autre : Céphalées, Circulation sanguine et lymphatique

Declaration 349415, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Tanacetum parthenium (L.) Sch.Bip.Parties aériennesAlcoolature1.3 g

Other ingredients

Eau purifiée, Alcool

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Contient de l’alcool. Ne pas dépasser la dose journalière recommandée. Ne se substitue pas à une alimentation variée et équilibrée et à un mode de vie sain. Tenir hors de portée des enfants. Déconseillé chez les enfants de moins de 18 ans, femmes enceintes ou allaitantes. Déconseillé en cas d'allergie aux plantes de la famille des astéracées. Demander un avis médical en cas de prise concomitante de médicaments (anticoagulants ou antiagrégants plaquettaires). Conserver dans un endroit frais et sec, à l’abri de la lumière. Agiter avant emploi.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Tanacetum parthenium (L.) Sch.Bip.
    Read the warning, when it applies and the studies cited

    FEVERFEW - TANACETUM PARTHENIUM

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).

    Sources cited by Health Canada (2)
    • Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;320(8301):776. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).

    Sources cited by Health Canada (1)
    • Boon H. Feverfew. In: Chandler F, editor. Herbs: Everyday Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association and the Canadian Medical Association; 2000.

    Contraindications

    Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.

    Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Applies to products providing more than 250 mg of dried herb top and/or leaf, per day.

    Do not use if you are pregnant or breastfeeding (EMA 2020).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).

    Sources cited by Health Canada (2)
    • Hausen BM. A 6-year experience with compositae mix. American Journal of Contact Dermatitis 1996;7(2):94-99. PubMed
    • Paulsen E, Anderson KE and Hausen BM. Sensitization and cross-reaction patterns in Danish Compositae-allergic patients. Contact Dermatitis 2001;45(4):197-204. PubMed

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).

    Sources cited by Health Canada (3)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Johnson ES, Kadam NP, Hylands DM, Hylands PJ. 1985. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal 291(6495):569-573.
    • Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;332(8604):189-192.

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Les enracinées

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Extrait hydro-alcoolique de grande camomille 50 ml (Les enracinées): composition and regulation”, https://compoatlas.com/en/supplements/products/349415-extrait-hydro-alcoolique-de-grande-camomille-50-ml, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line